Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Krista Ziesman

Nurse Practitioner Tampa, FL Nurse Practitioner

NPI 1518338318 CMS profile 10971062

2 Tampa General Cir Fl Stc4, Tampa, FL 33606

Open in the dashboard

General payments

$15,237

709 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Krista Ziesman of Tampa, FL is reported in the CMS Open Payments database as having received $15,237 across 709 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,466 143
2024 General $3,217 139
2023 General $3,282 156
2022 General $3,214 163
2021 General $2,058 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Krista Ziesman
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Krista Ziesman were reported at $3,466. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Krista Ziesman Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,058 $135 $40–$426 $132
2022 $3,214 $152 $48–$470 $149
2023 $3,282 $166 $54–$529 $160
2024 $3,217 $173 $55–$556 $164
2025 $3,466 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $2,410 141 payments
  2. AstraZeneca Pharmaceuticals LP $2,234 114 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,699 73 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $869 42 payments
  5. Genzyme Corporation $854 32 payments
  6. Grifols USA, LLC $606 23 payments
  7. Regeneron Healthcare Solutions, Inc. $594 22 payments
  8. ANI Pharmaceuticals, Inc. $504 18 payments
  9. Jazz Pharmaceuticals Inc. $496 21 payments
  10. United Therapeutics Corporation $420 18 payments
  11. Other $4,551 205 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,237 709 payments
Products named General payments · program years 2021–2025
  1. GLASSIA $1,699 73 payments
  2. TRELEGY ELLIPTA $1,589 98 payments
  3. FASENRA $998 41 payments
  4. DUPIXENT Immunology $854 32 payments
  5. NUCALA $821 43 payments
  6. BREZTRI $629 23 payments
  7. Prolastin-C Liquid $606 23 payments
  8. OFEV $579 29 payments
  9. DUPIXENT Inflammation And Immunology $558 21 payments
  10. TEZSPIRE $551 23 payments
  11. Other $7,440 319 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

709 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record